-
2025-523975-48-00
5
2026-05-08
Obesity
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523938-10-00
5
2026-05-05
Diabetic Macular Edema (DME)
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-521936-12-00
5
2026-04-24
Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline re
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-522231-34-00
5
2026-03-31
Diabetic Macular Edema
-
2025-521730-28-00
4
2026-03-30
Colorectal Cancer with Cancer Cachexia
-
2025-522578-35-00
4
2026-03-30
Atopic Dermatitis
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-521036-11-00
5
2026-03-23
Immune system disseases
-
2025-522232-13-00
4
2026-03-06
Sepsis-associated acute kidney injury (AKI)
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-523706-32-00
3
2026-02-17
not applicable (submitted trial is a pharmacokinetic study in healthy
-
2024-516966-12-00
4
2026-02-13
Alzheimer’s disease
-
2025-522514-23-00
5
2026-02-12
Urinary Incontinence
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease